Haleon PLC 预期股息率 % : 2.58% (今日)
Haleon PLC预期股息率 %(Forward Dividend Yield %)的相关内容及计算方法如下:
预期股息率 %是预期未来12个月的股息与当前股价之间的比率。 截至今日, Haleon PLC 的 预期股息率 % 为 2.58%。
Haleon PLC预期股息率 %或其相关指标的历史排名和行业排名结果如下所示:
★ ★ ★ ★ ★
在医药制造内的 255 家公司中
Haleon PLC的预期股息率 % 排名高于同行业 61.96% 的公司。
当前值:2.58 行业中位数:2.09
安全信号
股利分红: 股息率 % 接近2年高点
截至2024年3月, Haleon PLC 过去一季度 的 股息支付率 为 0.92。
Haleon PLC 1年每股股利增长率 % 为 150.00%。
Haleon PLC 预期股息率 % (HLN 预期股息率 %) 行业比较
在专用医药制造(三级行业)中,Haleon PLC 预期股息率 %与其他类似公司的比较如下:
Haleon PLC 预期股息率 % (HLN 预期股息率 %) 分布区间
在医药制造(二级行业)和医疗保健(一级行业)中,Haleon PLC 预期股息率 %的分布区间如下:
Haleon PLC 预期股息率 % (HLN 预期股息率 %) 计算方法
预期股息率 %是预期未来12个月的股息与当前股票价格之间的比率。在投资实践中,股息率是衡量企业是否具有投资价值的重要标尺之一。价值大师(GuruFocus)的预期股息率 %由数据供应商直接提供。
Haleon PLC 预期股息率 % (HLN 预期股息率 %) 解释说明
从长远来看,股息收益是股票投资总收益的重要贡献之一。普林斯顿大学的Elroy Dimson,Paul Marsh和Mike Staunton(2002年)的研究发现,以市场为导向的投资组合在包括股利再投资的情况下,所产生的财富几乎是同一个投资组合仅依靠资本收益获得的财富的85倍。
股息也可能使投资者享有较低的税率。
Haleon PLC 预期股息率 % (HLN 预期股息率 %) 相关词条
感谢查看价值大师中文站为您提供的Haleon PLC预期股息率 %的详细介绍,请点击以下链接查看与Haleon PLC预期股息率 %相关的其他词条:
Haleon PLC (HLN) 公司简介
一级行业:医疗保健
二级行业:医药制造
公司网站:https://www.haleon.com
公司地址:The Heights, Building 5, First Floor, Surrey, Weybridge, GBR, KT13 0NY
公司简介:Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
二级行业:医药制造
公司网站:https://www.haleon.com
公司地址:The Heights, Building 5, First Floor, Surrey, Weybridge, GBR, KT13 0NY
公司简介:Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.